U.S. Rx Trends Showing Impact Of Fewer Drug Approvals, IMS Data Suggest

New prescription growth rates in the U.S. appear to reflect a drop-off in the number of new drugs clearing FDA, IMS VP-Industry Relations Doug Long told the Pharmaceutical Care Management Association annual meeting Oct. 14 in Henderson, Nev.